Eye on Innovation
digital therapeutics
- Prescription Digital Therapeutics for Mental Health: Effectiveness, Challenges, and Future Trends
- Otsuka and Click Therapeutics Announce the U.S. Food and Drug Administration (FDA) Clearance of Rejoyn™, the First Prescription Digital Therapeutic Authorized for the Adjunctive Treatment of Major Depressive Disorder (MDD) Symptoms
- Where Do We Go from Here on Digital Therapeutics?
- Dartmouth Joins International AI Alliance
- From Ideas to Impact: Symposium on Digital Therapeutics
- Updates in Federal Legislation Addressing Digital Therapeutics, Access to Care
- Dartmouth to Host Summit on Digital Therapeutics
- FDA Forms New Digital Health Advisory Committee to Cover Growing Role of Tech
- Experts Discuss AI Use Across Fields at Conference